文献速递心脑血管急症复苏、休克与脓毒症

抗心律失常药治疗院外心脏骤停的比较有效性:系统评价与网络Meta分析

Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis.
PubMed 文献 · Resuscitation · 2017-10-14
一句话结论网络Meta分析显示,胺碘酮和利多卡因与院外心脏骤停患者入院存活率提高相关,但无任何抗心律失常药改善出院存活或神经功能完好存活。

该系统评价与网络Meta分析纳入8项RCT共4464例非创伤性院外心脏骤停成人患者,比较5种抗心律失常药与安慰剂在复苏期间给药的效果。利多卡因与安慰剂相比显著提高自主循环恢复(RR 1.15,95%CI 1.03-1.28),且优于溴苄铵(RR 1.61,95%CI 1.00-2.60)。胺碘酮(RR 1.18,95%CI 1.08-1.30)和利多卡因(RR 1.18,95%CI 1.07-1.30)与安慰剂相比显著提高入院存活率。但无任何抗心律失常药在出院存活或神经功能完好存活方面显著优于安慰剂,也无药物在任何结局上令人信服地优于其他药物。

要点

  • 利多卡因与安慰剂相比显著提高自主循环恢复(RR 1.15,95%CI 1.03-1.28),且优于溴苄铵(RR 1.61,95%CI 1.00-2.60)。
  • 胺碘酮(RR 1.18,95%CI 1.08-1.30)和利多卡因(RR 1.18,95%CI 1.07-1.30)与安慰剂相比显著提高入院存活率。
  • 无任何抗心律失常药在出院存活或神经功能完好存活方面显著优于安慰剂。
  • 无任何抗心律失常药在任何结局上令人信服地优于其他药物。
  • 共纳入8项RCT、4464例成人非创伤性院外心脏骤停患者,比较5种抗心律失常药与安慰剂。

适用人群与场景

  • 成人(≥18岁)非创伤性院外心脏骤停患者,在复苏期间接受抗心律失常药物治疗。

研究设计与关键结果

  • 研究类型:系统评价与网络Meta分析,纳入8项RCT,共4464例患者,比较5种抗心律失常药与安慰剂。
  • 主要终点:利多卡因与安慰剂相比显著提高自主循环恢复(RR 1.15,95%CI 1.03-1.28);利多卡因优于溴苄铵(RR 1.61,95%CI 1.00-2.60)。
  • 入院存活:胺碘酮(RR 1.18,95%CI 1.08-1.30)和利多卡因(RR 1.18,95%CI 1.07-1.30)与安慰剂相比显著提高。
  • 出院存活和神经功能完好存活:无任何抗心律失常药显著优于安慰剂;无任何药物在任何结局上令人信服地优于其他药物。

证据类型、等级与局限

  • 证据类型:系统评价与网络Meta分析(RCT),采用频率学派固定效应模型,GRADE方法评估证据确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于成人非创伤性院外心脏骤停,胺碘酮和利多卡因是网络Meta分析中唯一与入院存活率提高相关的药物。
  • 对于患者最重要的结局(出院存活和神经功能完好存活),无任何抗心律失常药令人信服地优于其他药物或安慰剂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite their wide use in the prehospital setting, randomized control trials (RCTs) have failed to demonstrate that any antiarrhythmic agent improves survival to hospital discharge following out-of-hospital cardiac arrest.

OBJECTIVE: To assess the use of antiarrhythmic drugs for patients experiencing out-of-hospital cardiac arrest (OHCA).

METHODS: Electronic searches of Medline, EMBASE and Cochrane Central Register of Controlled Trials were conducted and reference lists were hand-searched. Randomized controlled trials (RCTs) investigating the use of antiarrhythmic agents administered during resuscitation for adult (≥18years) patients suffering non-traumatic OHCA were included. Direct and indirect evidence were combined in a network meta-analysis (NMA) using a frequentist approach with fixed-effects models and reported as relative risks (RR) with 95% confidence intervals (CIs). For each pairwise comparison, the certainty of direct, indirect, and network evidence was assessed using the GRADE approach.

RESULTS: 8 RCTs involving 4464 patients were combined to compare the effectiveness of 5 antiarrhythmic agents and placebo administered during resuscitation following OHCA. Lidocaine was associated with a statistically significant increase in ROSC compared to placebo (1.15; 95% CI: 1.03-1.28) and was also superior to bretylium (1.61; 95% CI: 1.00-2.60) for ROSC. When compared to placebo, both amiodarone (1.18; 95% CI: 1.08-1.30) and lidocaine (1.18; 95% CI: 1.07-1.30) were associated with a statistically significant increase in survival to hospital admission. However, no antiarrhythmic was statistically more effective than placebo for survival to hospital discharge or neurologically intact survival, and no antiarrhythmic was convincingly superior to any other for any outcome.

CONCLUSIONS: Amiodarone and lidocaine were the only agents associated with improved survival to hospital admission in the NMA. For the outcomes most important to patients, survival to hospital discharge and neurologically intact survival, no antiarrhythmic was convincingly superior to any other or to placebo.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. McLeod SL, Brignardello-Petersen R, Worster A, et al. Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis. Resuscitation. 2017. PMID: 29037886. doi:10.1016/j.resuscitation.2017.10.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。